Cart
sales@molnova.com
Inotuzumab
CAS No. 1660159-36-3
Inotuzumab( —— )
Catalog No. M36722 CAS No. 1660159-36-3
Inotuzumab (Humanized Anti-CD22 Recombinant Antibody) is a humanized IgG4 antibody targeting CD22.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 347 | Get Quote |
|
| 5MG | 550 | Get Quote |
|
| 10MG | 882 | Get Quote |
|
| 25MG | 1260 | Get Quote |
|
| 50MG | 1702 | Get Quote |
|
| 100MG | 2232 | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameInotuzumab
-
NoteResearch use only, not for human use.
-
Brief DescriptionInotuzumab (Humanized Anti-CD22 Recombinant Antibody) is a humanized IgG4 antibody targeting CD22.
-
DescriptionInotuzumab (Humanized Anti-CD22 Recombinant Antibody) is a humanized IgG4, κ antibody that targets human CD22. Inotuzumab can be linked to a toxic agent ozogamicin as an antibody-drug conjugate (ADC). Inotuzumab can be used for the research of acute lymphoblastic leukemia and non-Hodgkin lymphoma.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorADC Antibody
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1660159-36-3
-
Formula WeightApproximately 146.48 kDa.
-
Molecular Formula——
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Aujla A, et al. Inotuzumab ozogamicin in clinical development for acute lymphoblastic leukemia and non-Hodgkin lymphoma. Biomark Res. 2019 Apr 11;7:9.?
molnova catalog
related products
-
Indigo carmine
Indigo carmine is an indolesulfonic acid. It is used as a dye in renal function testing for the detection of nitrates and chlorates.
-
8-Prenylkaempferol
8-Prenylkaempferol is an effective agent for attenuating pro-inflammatory NO induction, it may be an anti-inflammatory agent for suppressing influenza A virus-induced RANTES production acts by blocking PI3K-mediated transcriptional activation of NF-κB and IRF-3 and in part by interfering with IκB degradation which subsequently decreases NF-κB translocation.
-
MBC-11
MBC-11 is a first-in-class conjugate of the bone-targeting bisphosphonate etidronate covalently linked to the antimetabolite cytarabine (araC), with potential to treat tumor-induced bone disease (TIBD).
